TY - JOUR
T1 - Dihydroergocryptine in the treatment of Parkinson's disease
T2 - A six months' double-blind clinical trial
AU - Martignoni, E.
AU - Pacchetti, C.
AU - Sibilla, L.
AU - Bruggi, P.
AU - Pedevilla, M.
AU - Nappi, G.
PY - 1990
Y1 - 1990
N2 - The short-term efficacy of dihydro-α-ergocryptine (DEK), a hydrogenate ergot derivative with dopamine (DA) agonist properties was evaluated in 20 L-dopa (LD) stable responder parkinsonian patients by a 6-month double-blind randomized, placebo-controlled study. A motor improvement was found only in DEK-treated patients at mean daily doses of ~40 mg, ranging from 15 to 60 mg. The side effects never required the withdrawal of the drug or changes in its schedule. The authors demonstrate the efficacy and the good tolerability of DEK as a new DA agonist drug that can be added to LD in the treatment of parkinsonian patients.
AB - The short-term efficacy of dihydro-α-ergocryptine (DEK), a hydrogenate ergot derivative with dopamine (DA) agonist properties was evaluated in 20 L-dopa (LD) stable responder parkinsonian patients by a 6-month double-blind randomized, placebo-controlled study. A motor improvement was found only in DEK-treated patients at mean daily doses of ~40 mg, ranging from 15 to 60 mg. The side effects never required the withdrawal of the drug or changes in its schedule. The authors demonstrate the efficacy and the good tolerability of DEK as a new DA agonist drug that can be added to LD in the treatment of parkinsonian patients.
KW - Dihydro-α-ergocryptine (DEK)
KW - Dopamine agonists
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=0025613713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025613713&partnerID=8YFLogxK
M3 - Article
C2 - 1903079
AN - SCOPUS:0025613713
VL - 14
SP - 78
EP - 83
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
SN - 0362-5664
IS - 1
ER -